Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776655 | 0.87 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL1110755 | 0.85 | VCAM1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL30695462 | 0.84 | ACLY (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19475371 | 0.84 | ACLY (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21962449 | 0.83 | CA2 (0.54) | CA1CA2CA9CA12CA14 | |
| SCHEMBL31704382 | 0.83 | ACLY (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21623272 | 0.82 | ALDH1A1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL11372105 | 0.82 | CA1 (0.63) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13545951 | 0.82 | CA1 (0.53) | CA1CA2CA9CA12CA14 | |
| SCHEMBL9084469 | 0.82 | CA1 (0.53) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58192820-A | — | — | None | — | — | JP | disclosed |
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-3445756-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3445756-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2838519-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIV COLLEGE DUBLIN NAT UNIV OF IRELAND DUBLIN (IE) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017184623-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| EP-2838520-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2838519-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A9 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-01-08 | — | — | WO | disclosed |
| WO-2013156871-A2 | THROMBOXANE RECEPTOR ANTAGONISTS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013156861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2013-10-24 | — | — | WO | disclosed |
| US-6057322-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
| US-5292755-A | USPA benzolyguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | disclosed |
| US-5091394-A | BENZOYLGUANIDINES, A PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| JP-S58192820-A | ANTIVIRAL MEDICINAL COMPOSITION | MOCHIDA PHARMACEUT CO LTD | 1983-11-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CA1 4294/4885CA2 2191/4885CA9 3437/4885 |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA1 4294/4885CA2 2191/4885CA9 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.